4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02), FiscalAI reports. 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%. The firm had revenue of $3.78 million for the quarter, compared to analysts’ expectations of $3.62 million.
4D Molecular Therapeutics Stock Performance
NASDAQ FDMT traded down $0.22 on Thursday, reaching $11.65. 705,798 shares of the company’s stock traded hands, compared to its average volume of 787,133. The firm has a market cap of $609.06 million, a price-to-earnings ratio of -4.53 and a beta of 2.73. The stock has a 50 day moving average price of $10.84 and a 200-day moving average price of $9.83. 4D Molecular Therapeutics has a fifty-two week low of $5.97 and a fifty-two week high of $14.00.
Wall Street Analyst Weigh In
FDMT has been the subject of several recent analyst reports. Wall Street Zen lowered shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. B. Riley Financial initiated coverage on shares of 4D Molecular Therapeutics in a research note on Friday, July 31st. They issued a “buy” rating and a $37.00 target price for the company. Chardan Capital raised shares of 4D Molecular Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research report on Monday, July 20th. Finally, The Goldman Sachs Group set a $33.00 price objective on 4D Molecular Therapeutics in a research report on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.75.
Insider Activity
In other 4D Molecular Therapeutics news, insider Scott Bizily sold 9,810 shares of 4D Molecular Therapeutics stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total transaction of $117,720.00. Following the completion of the transaction, the insider owned 8,617 shares in the company, valued at approximately $103,404. This trade represents a 53.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider David Kirn sold 12,415 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $10.05, for a total value of $124,770.75. Following the completion of the sale, the insider owned 871,737 shares in the company, valued at $8,760,956.85. The trade was a 1.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 197,226 shares of company stock worth $2,200,677 over the last ninety days. 7.90% of the stock is owned by insiders.
Institutional Investors Weigh In On 4D Molecular Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Janus Henderson Group PLC raised its position in shares of 4D Molecular Therapeutics by 164.4% in the fourth quarter. Janus Henderson Group PLC now owns 4,635,875 shares of the company’s stock worth $34,726,000 after acquiring an additional 2,882,508 shares during the period. State Street Corp boosted its stake in shares of 4D Molecular Therapeutics by 197.5% during the 4th quarter. State Street Corp now owns 2,688,880 shares of the company’s stock worth $20,167,000 after acquiring an additional 1,785,106 shares in the last quarter. RA Capital Management L.P. grew its position in shares of 4D Molecular Therapeutics by 23.9% during the 4th quarter. RA Capital Management L.P. now owns 5,653,211 shares of the company’s stock valued at $42,399,000 after acquiring an additional 1,090,000 shares during the period. Adage Capital Partners GP L.L.C. increased its stake in shares of 4D Molecular Therapeutics by 605.8% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,235,156 shares of the company’s stock valued at $9,264,000 after purchasing an additional 1,060,156 shares in the last quarter. Finally, Armistice Capital LLC increased its stake in shares of 4D Molecular Therapeutics by 265.3% in the 3rd quarter. Armistice Capital LLC now owns 1,096,000 shares of the company’s stock valued at $9,524,000 after purchasing an additional 796,000 shares in the last quarter. Institutional investors and hedge funds own 99.27% of the company’s stock.
4D Molecular Therapeutics Company Profile
4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.
4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.
Featured Articles
- Five stocks we like better than 4D Molecular Therapeutics
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
